Extended Endocrine Therapy and Survival for Breast Cancer Subtypes in Premenopausal Patients - Summary - MDSpire

Extended Endocrine Therapy and Survival for Breast Cancer Subtypes in Premenopausal Patients

  • By

  • Carmine Valenza

  • Yue Zheng

  • Monica Milano

  • Pier Paolo Maria Berton Giachetti

  • Dario Trapani

  • Elisa Giordano

  • Lorenzo Guidi

  • Laura Boldrini

  • Grazia Castellano

  • Jalissa Katrini

  • Bianca Malagutti

  • Gabriele Antonarelli

  • Julian D. Etessami

  • Nadia Bianco

  • Fabio Conforti

  • Gregory J. Kirkner

  • Claudia Sangalli

  • Kate E. Dibble

  • Nicola Fusco

  • Marco Colleoni

  • Meredith M. Regan

  • Elisabetta Munzone

  • Giuseppe Curigliano

  • Ann H. Partridge

  • May 4, 2026

  • 0 min

Share

Objective:

To evaluate the risk of invasive and distant recurrence among premenopausal women with node-positive, hormone receptor-positive early breast cancer who received or did not receive extended endocrine treatment (EET) after 5 years of adjuvant therapy, highlighting the significance of this evaluation in improving treatment strategies.

Key Findings:
  • Extended endocrine treatment was associated with lower rates of invasive and distant recurrence, suggesting a potential strategy for improving patient outcomes.
  • Over 70% of premenopausal patients had no evidence of recurrence 10 years post-treatment, indicating the effectiveness of the initial treatment.
  • Patterns of recurrence differ across luminal breast cancer subtypes, with luminal B-like tumors showing poorer outcomes, emphasizing the need for subtype-specific treatment approaches.
Interpretation:

The findings suggest that prolonged endocrine treatment may benefit premenopausal women with hormone receptor-positive breast cancer, particularly in refining treatment strategies based on breast cancer subtypes, while acknowledging the limitations in fully accounting for all influencing variables.

Limitations:
  • The study may not fully account for all variables influencing recurrence risk, such as genetic factors or lifestyle choices.
  • Data on long-term quality of life impacts from extended treatment were not comprehensively analyzed, which is crucial for understanding the overall benefit-risk ratio.
Conclusion:

Refining candidate selection for extended endocrine treatment is essential to optimize outcomes and manage quality of life in premenopausal women with hormone receptor-positive breast cancer, reinforcing the clinical relevance of these findings.

Original Source(s)

Extended Endocrine Therapy and Survival for Breast Cancer Subtypes in Premenopausal Patients

  • by Carmine Valenza, Yue Zheng, Monica Milano, Pier Paolo Maria Berton Giachetti, Dario Trapani, Elisa Giordano, Lorenzo Guidi, Laura Boldrini, Grazia Castellano, Jalissa Katrini, Bianca Malagutti, Gabriele Antonarelli, Julian D. Etessami, Nadia Bianco, Fabio Conforti, Gregory J. Kirkner, Claudia Sangalli, Kate E. Dibble, Nicola Fusco, Marco Colleoni, Meredith M. Regan, Elisabetta Munzone, Giuseppe Curigliano, Ann H. Partridge

  • May 4, 2026

Related Content

Peripheral blood monocytes could be associated with brain metastasis and affect patient prognosis in breast cancer: a retrospective study

Effects of SOX10 on the proliferative, invasive, migratory, and epithelial–mesenchymal transition abilities of triple-negative breast cancer cells

Dynamic changes and clinical significance of the gut microbiota and serum metabolites in breast cancer onset, progression and chemotherapy intervention